ReviewJournal of Cancer2022
Understanding the Dual Roles of CircHIPK3 in Tumorigenesis and Tumor Progression.
Review in Journal of Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 16 citations in OpenAlex.
- Bidirectional Interactions Between Immune Regulation and the Insulin-like Growth Factor Axis in Colorectal Cancer.International journal of molecular sciences · 2026Review
- Circular RNAs: Key Regulators of Tumor Metabolic Reprogramming and Clinical Translation.Oncology research · 2026Review
- Roles, mechanisms, and clinical implications of circHIPK3 in female malignancy: a comprehensive review.Discover oncology · 2025Review
- Exploring the roles and clinical potential of exosome-derived non-coding RNAs in glioma.IBRO neuroscience reports · 2025Review
- Biological functions and molecular mechanisms of circHIPK3 in digestive system tumors.Human cell · 2025Review
- Regulation of Different Types of Cell Death by Noncoding RNAs: Molecular Insights and Therapeutic Implications.ACS pharmacology & translational science · 2025Review
- Role of circular RNAs in cancer therapy resistance.Molecular cancer · 2025Review
- CircHIPK3's dual role in promoting angiogenesis and inhibiting apoptosis through FASN mRNA stabilization in gallbladder cancer.Clinics (Sao Paulo, Brazil) · 2025Article
- Circular RNA-based liquid biopsy: a promising approach for monitoring drug resistance in cancer.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- The landscape of circRNAs in gliomas temozolomide resistance: Insights into molecular pathways.Non-coding RNA research · 2024Review
- Review
- CircBRD7 attenuates tumor growth and metastasis in nasopharyngeal carcinoma via epigenetic activation of its host gene.Cancer science · 2024Article
- The potential of circHIPK3 as a biomarker in chronic myeloid leukemia.Frontiers in oncology · 2024Review
- Review
- Inverse Impact of Cancer Drugs on Circular and Linear RNAs in Breast Cancer Cell Lines.Non-coding RNA · 2023Article
- Recent advances and application value of circRNA in neuroblastoma.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CircHIPK3 is a type of endogenous circular RNA, which contains a covalently closed circular structure and cannot encode protein or polypeptide. CircHIPK3 is unusually expressed in varieties of tumors and plays dual roles of tumor promotion or tumor inhibition in tumorigenesis and development of tumors by serving as the sponge for miRNA in multiple tumors. Here, we reviewed the differential expression, the dual functions, the regulation mechanism, and the network in a variety of tumors as well as the potential value for the diagnosis and treatment of tumors, which are of great significance for our comprehensive understanding of the roles and mechanisms of circHIPK3 in tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.